Fluorouracil (5-FU): FDA Approval, Licensing in Türkiye, and Reimbursement Status
In this article
Fluorouracil (5-FU)has formed a backbone of cancer treatment since the 1950s, remaining an essential cytotoxic component of curative or palliative regimens, particularly for gastrointestinal cancers (colorectal, gastric, pancreatic) and breast cancer. Despite rapid advances in targeted agents and immunotherapy, 5-FU-based combinations (FOLFOX, FOLFIRI, FOLFIRINOX, FLOT) remain standard treatments.
- Main Role: A pyrimidine analog antimetabolite; it blocks thymidylate synthase, disrupting tumor cell DNA/RNA replication.
- Administration: Given by short bolus injection or continuous intravenous (IV) infusion over 46–48 hours using portable infusion pumps. A topical formulation is available for skin lesions.
- Critical Safety Warning (DPD Deficiency): The enzyme that breaks down more than 80% of the administered drug is DPD (dihydropyrimidine dehydrogenase) . In patients deficient in this enzyme's activity, 5-FU may cause fatal toxicity. Genetic/enzymatic screening before treatment can save lives.
- Oral Counterpart: Oral capecitabineis a prodrug converted into 5-FU through enzymatic steps in the liver and tumor tissue.
- Reimbursement and Access: Licensed in Türkiye and listed for SGK reimbursement without indication restrictions.
Fluorouracil (5-FU) Drug Profile
| Feature | Description |
|---|---|
| Active Ingredient | Fluorouracil (5-Fluoro-1H-pyrimidine-2,4-dione / 5-FU) |
| Drug Class | Antimetabolite (pyrimidine base analog), cytotoxic chemotherapy |
| Trade/Brand Names | Flouracil, Adrucil, Efudex (topical 5%), Fluoroplex, Carac |
| Administration Routes | Intravenous (IV bolus and continuous infusion), intra-arterial infusion, topical ointment/cream |
| First FDA Approval | 1962 (gastrointestinal carcinomas) |
| Licensing and Reimbursement in Türkiye | Licensed; on SGK's positive reimbursement list for all cancer diagnoses (covered by public insurance). |
| Main Indications | Colorectal cancer, gastric and gastroesophageal junction cancer, pancreatic cancer, breast cancer, head and neck cancer, actinic keratosis, and basal cell carcinoma (topical). |
Molecular Mechanism: What Happens in the Tumor Cell Nucleus?
Fluorouracil acts particularly during the S phase (DNA synthesis phase) of the cell cycle. After entering the cell, it produces cytotoxicity through three complementary active metabolites rather than a single step:
- Thymidylate Synthase (TS) Inhibition (FdUMP Pathway): Inside the cell, 5-FU is converted into 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) . FdUMP permanently binds thymidylate synthase, the key enzyme responsible for producing thymidine (dTMP), a building block of DNA. Binding with the folate coenzyme (5,10-methylenetetrahydrofolate) forms a stable ternary complex that locks the enzyme. Cellular dTMP pools are depleted, stopping DNA replication (“thymineless death”).
- Disrupted RNA Transcription and Function (FUTP Pathway): The ribonucleotide form, 5-fluorouridine triphosphate (FUTP) , is incorporated directly into RNA as an incorrect base. This abnormal incorporation prevents ribosomal RNA (rRNA) maturation, blocks mRNA functions, and disrupts cellular protein production.
- DNA Strand Breaks (FdUTP Pathway): 5-fluoro-2'-deoxyuridine triphosphate (FdUTP) is incorporated directly into DNA. As cellular repair mechanisms (apurinic/apyrimidinic endonucleases) try to remove these abnormal nucleotides, double-strand DNA breaks form and trigger apoptosis (programmed cell death).
History and Clinical Milestones of 5-FU
Fluorouracil Resistance: Why Does Treatment Fail?
Tumors initially responding very well may develop resistance over time, or they may be intrinsically resistant. The main biological mechanisms of 5-FU resistance are:
- Thymidylate Synthase (TS) Gene Amplification: Tumor cells produce excessive amounts of the target enzyme TS. Available drug is insufficient to saturate it, allowing DNA replication to continue.
- Increased DPD (Excessive Breakdown): Higher DPD activity in tumor tissue destroys the drug before it can be converted into cytotoxic metabolites.
- Transport Protein Defects: Reduced membrane proteins responsible for transporting 5-FU into cells, such as nucleoside transporters, decrease intracellular drug accumulation.
- Enhanced DNA Damage Repair: Mismatch repair (MMR) and nucleotide excision repair (NER) mechanisms that correct damage after abnormal nucleotide incorporation allow cells to survive.
- Apoptosis Resistance and p53 Mutations: Loss of function of p53, which prompts damaged cells to destroy themselves, or overexpression of anti-apoptotic Bcl-2 family proteins weakens the drug's cell-killing effects.
Clinical Dose Ranges and Combination Protocols
Fluorouracil is rarely used alone; synergistic combinations are central to current oncology practice. Common infusion schedules include:
| Cancer Type | Protocol/Regimen | Typical 5-FU Dose and Administration |
|---|---|---|
| Colorectal Cancer | FOLFOX / FOLFIRI / FOLFOXIRI | Initial 400 mg/m² IV bolus followed by 2400–3000 mg/m² continuous IV infusion over 46–48 hours through a port catheter pump (every 2 weeks). |
| Gastric and Esophageal Cancer | FLOT / CF Regimen | 2600 mg/m² continuous infusion over 24 hours (FLOT), or 800–1000 mg/m²/day continuous infusion for 4–5 days with cisplatin. |
| Pancreatic Cancer | Modified FOLFIRINOX | 2400 mg/m² continuous IV infusion over 46 hours; the bolus is often omitted to improve tolerability. |
| Breast Cancer | CMF Regimen | 500–600 mg/m² IV on days 1 and 8, with cyclophosphamide and methotrexate, in a 28-day cycle. |
| Head and Neck Cancer | TPF / PF Regimen | 1000 mg/m²/day by continuous IV infusion for 4–5 consecutive days, every 3 weeks with cisplatin/docetaxel. |
| Dermatology (Topical) | Actinic Keratosis / Superficial BCC | Apply a thin layer of 5% cream to lesions 1-2 times daily for 2–6 weeks. |
Genetic DPD deficiency is partial in approximately 3-8% of the population and complete in 0.1-0.2%, particularly with the DPYD*2A mutation. Giving standard-dose 5-FU to a DPD-deficient patient may cause profound neutropenic sepsis, extensive mucositis, uncontrolled bloody diarrhea, and mortality (death) approaching 100% . International authorities therefore recommend pretreatment blood screening with DPYD genetic testing or the uracil/dihydrouracil ratio.
Adverse Reactions: Frequency and Severity
| Adverse Reaction | Frequency | Clinical Presentation and Management |
|---|---|---|
| Mucositis and Stomatitis | 20% – 40% | Deep ulceration of the mouth and esophagus. Cooling (cryotherapy: sucking ice during infusion) substantially reduces damage with bolus administration. |
| Diarrhea | 20% – 35% | Caused by intestinal epithelial damage. Loperamide and aggressive hydration are required; persistent cases require dose modification. |
| Myelosuppression (Neutropenia/Anemia) | 25% – 40% | Reduced white blood cell counts increase infection risk. G-CSF growth factors may be required. More frequent with bolus protocols than infusion. |
| Hand–Foot Syndrome (PPE) | 10% – 25% | Occurs particularly with prolonged infusion or oral capecitabine. Redness, peeling, and pain affect the palms and soles. Urea-containing creams and pyridoxine (B6) are used. |
| Cardiotoxicity (Coronary Vasospasm) | 1% – 5% | Chest pain, angina, or an infarction-like presentation caused by coronary artery spasm. If symptoms occur, stop the infusion immediately and give nitrates/calcium channel blockers. |
Critical Drug Interactions
- Warfarin (Coumadin): 5-FU inhibits cytochrome enzymes, preventing warfarin breakdown. INR may rapidly rise above 10 and cause fatal internal bleeding. Weekly INR monitoring is essential; switch to low-molecular-weight heparins such as enoxaparin if possible.
- Brivudine and Sorivudine (Antivirals): These antivirals used for shingles irreversibly inhibit DPD. Concurrent use with 5-FU is strictly CONTRAINDICATED because of life-threatening toxicity. At least 4 weeks must separate their use.
- Leucovorin (Folinic Acid): Intentionally given in combination to enhance effectiveness, but this synergy also increases the severity of mucositis and neutropenia.
- Phenytoin: May raise blood phenytoin concentrations dangerously, causing central nervous system toxicity.
Licensing, SGK Reimbursement, and Prices in Türkiye
Fluorouracil is an essential medicine approved by the Turkish Medicines and Medical Devices Agency (TİTCK), routinely used in oncology clinics, with domestically produced and imported generic formulations. Under the Health Implementation Communiqué (SUT), without restrictions on indication matching for a cancer diagnosis , it is directly reimbursed by SGK.
5-FU is among the least expensive oncology medicines through public procurement and retail channels. Depending on dose, vial formulations cost approximately 100 TL - 250 TL per pack; inpatient/day-case protocols funded by hospital budgets impose no additional financial burden on patients. Current prices are periodically revised according to TİTCK price lists and exchange-rate updates.
DROZDOGAN ACADEMY COMMENTARY
With a history exceeding 60 years, fluorouracil is a clear example challenging the misconception that older medicines have little value in oncology.
⚡ Why Is It Still Essential?
New-generation targeted agents, monoclonal antibodies (bevacizumab, cetuximab, panitumumab), and immunotherapies achieve success in gastrointestinal tumors, but 5-FU-based regimens (FOLFOX, FOLFIRI) almost always form the backbone of this success. Without 5-FU, the effectiveness of these targeted agents alone falls dramatically.
✅ Bolus Versus Infusion: Biological Elegance
In clinical oncology, how 5-FU is given matters as much as how much is given. A bolus (a brief intravenous push) targets RNA synthesis and causes more bone marrow suppression (neutropenia). Continuous infusion over 46-48 hours directly targets DNA synthesis (thymidylate synthase), producing less hematological toxicity but more hand–foot syndrome. Their balance in modern protocols reflects this pharmacodynamic distinction.
⚠️ A Neglected Area of Modern Oncology: DPYD Testing
5-FU is a safe molecule, but in the small group with DPD deficiency it effectively becomes a poison. Guidelines in Western Europe and the United States strongly recommend pretreatment testing. In Türkiye, clinical awareness should likewise increase regarding routine pretreatment DPYD screening. A simple genetic analysis in advance can completely prevent unforeseen toxicities.
🩺 Practical Summary for Patients and Physicians
- Monitoring a Port Pump at Home: Patients returning home with a 46-hour infusion pump should check its flow rate, whether the reservoir is deflating, and redness at the port entry site.
- Watch for Chest Pain: Unexplained chest pressure or breathlessness during infusion must be reported to the oncologist immediately; coronary vasospasm risk must not be overlooked.
- Oral Care: Baking soda mouth rinses started on treatment day, together with oral hygiene, are the most effective and inexpensive way to prevent severe mucositis episodes.
Sources and Scientific References
- Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957;179(4561):663-666.
- Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330-338.
- Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2020 Update. Clin Pharmacol Ther. 2020;107(5):867-875.
- European Medicines Agency (EMA). EMA recommendations on DPD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine. 2020.
- T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu (TİTCK). Fluorouracil Kısa Ürün Bilgisi (KÜB).
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.